Impact of Brimonidine on the Cornea
Conditions
Keywords
brimonidine, alpha-2 adrenoceptor, cornea, corneal thickness
Brief summary
Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out 1. whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and 2. whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.
Interventions
DRUGplacebo
sodium hyaluronate 1.8mg/ml eye drops twice daily
DRUGbrimonidine 0.1%
brimonidine 0.1% eye drops twice daily
Sponsors
Augenarztpraxis Breisach
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* healthy, 18-99 years, normal ophthalmologic history, consent to participate in the study
Exclusion criteria
* any serious medical or neurologic conditions and/or regular use of local or systemic medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| corneal thickness | 5 days |
Secondary
| Measure | Time frame |
|---|---|
| intraocular pressure | 5 days |
Countries
Germany
Contacts
Primary ContactMatthias Grueb, Priv. Doz. Dr.
Outcome results
None listed